today's call. to for morning, want us thank on and good Andrea, Thanks, everybody everyone. I joining
an in the today's we on commercial unaudited results significant our activities. and key metrics As the final issued fourth year-end and also will fourth provide commercial you early may year-end preliminary we provide with We'll numbers call, XXXX. noted, for audited the quarter update highlights for Including you LUPKYNIS. quarter On January. have and
of strategy business plan announced company to company's then restructure our review our allows near-term plan We a includes I over immediate repurchase and We to picture. details, to turn strategic with enhancement of the will believe the and moving the program. update these provide After value the forward. on company's Joe financial the share then an the initiation previously provide This will you walking for Miller, and through our this our call strengthen has results. long-term details to additional financial CFO, shareholder ability
the product $XXX.X full XX% the approximately total For increase revenue, XXXX, which net of net over year represented million an in XX% in representing increase million achieved We year. achieved an Aurinia XXXX. of $XXX.X revenue, prior over
the fourth total quarter the represented an rep and XXXX. same in of For a a increase million and net achieved of XX% we of $XX.X million $XX.X revenue period revenue XX% product over which total of XXXX,
results. Moving detail to behind more financial our
quarter, Aurinia start quarter the XXX PSF, in patient And XXXX. PSFs During added of XXX in the fourth forms of third quarter fourth or the XXX compared to XXXX.
a both time. considerable that a for know back company channel. additional The We growth in numbers of hospital fourth includes the on defined to restarts a as the achieved PSF therapy patients the to estimate therapy added channel XXX patient and the new also new for the for are they've restarting. addition coming before XXX who added fourth beginning patients This require quarter, In reported significance since restart and patients patients patients. hospital new in have addition numerical not Hospital coming restarts, of do through been therapy of and amount indicators time newly approximately in first the of quarter off an are PSFs restart the us.
importance I'll the of therapy, aligned is note Restarts physicians These demonstrate strategy that X are with continue of as a first-line is guidelines. using about for guidelines indicate years. for comfortable treatment our and flares to sustained encourage LUPKYNIS that and more remain a to they brand because not the call out aggressively. nephritis recent this maintaining LUPKYNIS the a treating talk in to there more most represent important on moment, indicator for strong a but time. patients commercial follow they guidelines for period the why X treat to lupus to we It's physicians likely therapy
into are we patients. Therefore, wallets the numbers, across wallet to all drug average ship dispensing to from to estimate how hospital those pharmacies, visibility wallets we how our hospitals little hospital with on patients based Regarding utilization patients. come no actual these many
market us to discussed, due X previously pandemic. launch first to the of global off hospital As the the for was years completely the closed
Now that at in we access, the we're care and have some complexities and approach inherent how integrated looking institutions these we broader are hospital the systems health a addressing of closely hospital networks. that
shipments We're our to and patients space beginning with wallet beginning impact pull to this the see through. the execution of in
same we increase total added number, X,XXX full of XX PSF, both PSF approximately year, February the XXXX restarts For approximately January an hospital added we X we have approximately PSFs. a the XXX from from the And year, to year-over-year. at X% the through of and channel. new X, patients Adding
with processing to that it XXXX, PSFs we Throughout point patients XX, less. report improving also takes starting of at XX a patients and continue In of to or addition, meaningful in days our improvement days XX% get rates that I'm We're our XX% this to speed XX like therapy. on therapy conversion converted improve periods, pleased approximately is our all year-over-year. therapy. increased I'd out time time with XX the to to
and persistency now improve XX%. continues to approximately is XX-month Our
at adherence XX% to almost strong with out who with at XX months holding of number approximately see prior steady to encouraged that remain months. at are consistent to on patients remains And treatment We XX LUPKYNIS therapy year-end. XX% periods,
speeds therapy and of increase XXXX. new of XXXX, processing patients represents and overall predominantly XX% driven over PSF, was Exiting increase patient total improvements this conversion in over quarter in in fills, hospital persistency. improvements The an the rates by restarts, on a in
As Educating screen LUPKYNIS to as position KDIGO our updated clinical and in on on areas: and continuing care lastly, health on key we and grow discuss market the LUPKYNIS and ULAR to address clinically on proactively need screening providers second, part by and it treat continue data leaders increase we professionals and treatment our of lupus to lupus strategy differentiate previous is nephritis leveraging To activating long-term opinion aggressively; more three the physicians; their in with guidelines. care it stated of health to key calls, to the nephritis. patient foundation treatment the our and focused focus the therapy first, the
and an messaging at therapy these to therapies following physicians response. are sales patients SLE at through and marketing SLE monitoring Start And that to be use. minimize [ X every complete on Prioritizing for diagnosis will with developments, our response. with least is treat to we with encouraging We're to lastly, to efforts. increased for and from to Met ] reducing goals combination X nephritis clinical recognize combination steroid patients and effective treatment protein levels messaging active years continue screening risk Our patient, of this all meaningful treating lupus early critical. routinely that for focus and seeing in leverage may nephritis lupus continuing reinforce robust the target goal impact renal a already renal
on to and we In educating SLE terms their activation, focus them with driving nephritis provocative conversations screening and efforts in our of physicians lupus and patients have about treatment. patient proactive
highly and the start lupus and nephritis on advocacy as stay reinforces the to deliver messages social urine targeted messaging initiatives of We in-person progressing Our the importance digital of critical the through these as events. need mix screening, and seriousness of routine threat a of well treatment.
story teams potential writers. towards the LUPKYNIS clinical on focused and Finally, our delivering customer-facing highest the are differentiation targeted clinical
to Please review provide customers, against on to within XX-K guidance find Annual new have in like annual the and quarter, General our $XXX and And the our connection new based Building and I'd since located X,XXX related held report and now the And the our we steadily XXXX. established fourth press Meeting current company release. strategic To we've of in in the revenue activities in momentum remind quarter, everyone certain discuss base XX, review of targets with context. how discussed of Our got net these strategic we launch. in depth expanded shareholders everything gears, to a addition, writers. fourth we product review prescribing on XXXX, the that over details desire customers issued we're further further recently range will May throughout our here, increased now increased Shifting for our you today, of XXXX process. on PSF reaffirming additional $XXX million we have note undergo their the million. express of Form conclusion
new company's majority the Those submitted most company's the not significant of two and and majority our voting nominees the AGM, accordingly to agreed policy voclosporin directors Board. requisite members and XXXX with collaboration additionally, Dr. the did both to receive resignation And Foster, for the agreement Board. in At two connection replaced senior were the experienced under backgrounds. resigning inventor entered directors, shareholder, their with business we with with that of development appoint into one we pharma Robert to
of exploration sale, the the range or company It on shareholders noted results including, company, lead not XX, that wide expressed strategic of AGM strategic that initiated merger company June to, JPMorgan transactions. alternatives. as for the the it strategic would Given potential other the the as retained financial certain had consider as a but of The by well the XXXX, a announced was desires review. options to adviser its limited process
Aurinia process. the comprehensive data of a support and room, materials JPMorgan to corporate the and review overall Following the put a announcement together process, presentation
parties. JPMorgan agreements XX with being led nondisclosure then that parties, signed XX engage than to potentially more engagement interested with
also of formal to of only our did counterparty strategic Board significant containing the preliminary and a formal diligence of nondisclosure X,XXX not extensive, interest, that interest, across which to a detailed a process. Aurinia's review conditions, not process, its basis. formal due expression XXX,XXX was After the some of a elected sign diligence. including Aurinia party nonbinding room of to remains its pages one submitted that management into on of subject to meetings allow The effort alternatives presented elected and a files. the customary offer. into nonconfidential party that conclusion from put expression At Despite a submit materials conducted including board, diligence multiple agreements exploration advisers, over data Marine's multiple itself parties
or Aurinia explored assets. multiple addition including potential the exploring the to of In merging also the for sale company, acquiring, or licensing entities other alternatives
the commercial available The company's the the Board and the Board company as management the on best of we're it path to pursue interest announced of its Based forward other is ultimately and execution. this determined to believes the that and best outcome that of alternatives the none operations shareholders. we're explored that extensive streamline review, the focus today, for strategic to on in
with term to in expect We time, to meaningful this provide continue we shares and the cash us to build repurchase to sheet create short balance to over redeploy flow strength. financial intend which firepower
next to we believe mission. our diversifying with include could of As allow will creating flexibility the assets wide drive company financial or portfolio through to grow pipeline through of alternatives consider commercial range to or continue few new its towards the other the assets years. This of scale addition acquisition that over a and the the strategies
which nonbinding did For at the process, the leading extensive expression strategic a company confidential not one offer. previous conducted a end, company interest, a the and engaged received the only bank investment even XXXX, in in After direction, more and but of outreach, context, formal due process. management diligence a result review in included under Board's
receives. And that the open to any has any company outside of to remain bona offer any interest The of and company never open opportunities are of interest, considering are the these offers company that two kind. expressions Board in best of the management, fide exploring though, received the
review, In flows. to strategic the and is enhancement by commitment its maintaining value focus maximizing on a addition, sharp following the reaffirming conclusion company cash of growth the while driving LUPKYNIS the efficiencies operating
charge restructuring million programs. headcount these be of the quarter AUR least both of Correspondingly, ceasing contract quarter employee or commercial XXXX. the There terminating the of This AUR approximately first roles. development result, anticipate to by no will by a and headcount severance expects XXX. company to company take at other of further the termination in end with up reducing of XXX reduction in a commercial made $XX planned first charge million $XX of As XXXX. is is costs, costs and and supporting associated costs XX% the We primarily
on expects our basis company of annual The savings impact to recognize on million approximately commercial to $XX cost $XX no investment. a with million go-forward
repurchase program subject shares, in continued share which regulatory Board short- both is amount This growth other reflects to shareholders approved up confidence the In maximum stakeholders. of has for Canada. value receipt and of of common to enhancing addition, commitment and prospects company's the approval a a in of Aurinia's $XXX to and million the long-term
that the then share up the for we return the your about Joe? as know of line details of more you call tell we will financial results. I quickly to additional can details repurchase now the of benefits. I Joe and maximize will While there to end this a program turn today for and recap execute provide detailed well shift, quick announced questions. of as call open timing review at and that, will decisively be to a questions the that strategic near-term With to our to the like over we I'd
